Posts

inch Therapeutics is slashing its headcount by around 37% and suspending its planned Phase I study in autism one week after Takeda withdrew from its multi-year collaboration, the company announced Thursday.

While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.

With an investment valued at up to $1.1 billion, Merck is diving back into Alzheimer’s research through a collaboration with Cerevance.

Thursday morning, Takeda reported its quarterly sales ending June 30, 2022. The company reported a 2.4% increase in revenue for the quarter from the same period in 2021, as well as changes to its pipeline, including a decision to drop a cancer therapeutic developed with Turnstone Biologics.

Just because it’s mid-July, that doesn’t mean clinical trial announcements are slowing down. This article reviews some of the more intriguing stories of the past week.